🇺🇸 FDA
Pipeline program

Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671

EFC17215 - LEAP2MONO

Phase 3 small_molecule active

Quick answer

Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671 for Gaucher's disease type III is a Phase 3 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pharma Bristol-Myers Squibb
Indication
Gaucher's disease type III
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials